TMCI Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
45.4M
-3.9%
47.2M
-24.5%
62.5M
+24.5%
50.2M
+6.0%
47.4M
Cost of Revenue
9.8M
-0.2%
9.8M
-19.2%
12.1M
+15.3%
10.5M
+9.1%
9.6M
Gross Profit
35.6M
-4.8%
37.4M
-25.8%
50.4M
+26.9%
39.7M
+5.2%
37.8M
Operating Expenses
50.4M
-7.7%
54.6M
-3.1%
56.3M
+1.7%
55.4M
+1.4%
54.6M
R&D
4.4M
-5.3%
4.6M
+1.8%
4.5M
-2.9%
4.7M
-14.9%
5.5M
SG&A
46.2M
-7.5%
50.0M
-3.5%
51.8M
+2.1%
50.7M
+3.0%
49.2M
Operating Income
-14756000
+14.0%
-17167000
-189.9%
-5922000
+62.2%
-15676000
+7.0%
-16852000
EBITDA
-12868000
+20.9%
-16268000
-422.4%
-3114000
+75.9%
-12898000
+9.7%
-14276000
Net Income
-15873000
+11.6%
-17961000
-91.2%
-9394000
+42.3%
-16288000
+6.4%
-17398000
EPS (Basic)
$-0.24
+14.3%
$-0.28
-86.7%
$-0.15
+42.3%
$-0.26
+7.1%
$-0.28
EPS (Diluted)
$-0.24
+14.3%
$-0.28
-86.7%
$-0.15
+42.3%
$-0.26
+7.1%
$-0.28
Shares (Diluted)
65.0M
+0.7%
64.6M
+1.1%
63.9M
+0.6%
63.5M
+0.8%
63.0M
Treace Medical Concepts (TMCI) โ€” Financials